Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07604571 2026-06-05

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Phase 1 Recruiting

194 enrolled

Breast

Advanced HR+/HER2- Breast Cancer

NCT05768139 2026-06-04

PIKALO-1

Phase 1/2 Recruiting

880 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05870579 2026-06-04

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Active not recruiting

48 enrolled

Breast

Breast Neoplasms

NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

1,050 enrolled

Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06756932 2026-06-04

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Phase 1 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT07174336 2026-06-04

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

920 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07288359 2026-06-04

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04567420 2026-06-03

DARE

Phase 2 Recruiting

70 enrolled

Breast

Breast Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Phase 1 Active not recruiting

134 enrolled

BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04916509 2026-06-02

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Completed

258 enrolled

Breast

Breast Neoplasms

NCT05038735 2026-06-02

EPIK-B5

Phase 3 Active not recruiting

210 enrolled

Breast

Breast Neoplasms

NCT03939897 2026-06-01

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Phase 1 Active not recruiting

24 enrolled 15 charts

Breast

Breast Neoplasms

NCT07618390 2026-06-01

A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.

Phase 2 Not yet recruiting

160 enrolled

Breast

Breast Neoplasms

NCT07619066 2026-06-01

AGATHA

Phase 2 Not yet recruiting

25 enrolled

Breast

Advanced Breast Cancer

NCT04862663 2026-05-27

CAPItello-292

Phase 3 Recruiting

895 enrolled

Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1 Recruiting

399 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05472792 2026-05-26

CAMERAN

Phase 2 Recruiting

90 enrolled

Breast

Breast Neoplasms

NCT00585507 2026-05-22

Efficacy and Safety of 500mg of Fulvestrant

Phase 2 Active not recruiting

40 enrolled

Breast

Breast Neoplasms

NCT05392608 2026-05-22

SEQUEL-Breast

Phase 2 Active not recruiting

130 enrolled

Breast

Breast Neoplasms, Genetic Diseases, Inborn

NCT07109726 2026-05-22

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Phase 1/2 Recruiting

205 enrolled

BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03425838 2026-05-20